Bharat Book

Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

Press Release   •   Dec 05, 2013 12:12 IST

Dec 5, 2013 : Bharat Book Bureau presents the new report, on ''Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors" provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of November 2012.

Product description
The present Competitive Intelligence Report about VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of November 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Novartis. The full length therapeutic antibody Avastin recorded sales of US$ 5.6 bln in the year 2011 and is mainly being used for treatment of colorectal, renal cell and non-small cell lung cancer (EU and US) as well as of breast cancer (EU) and glioblastoma (US). The humanized antibody fragment Lucentis marketed by Novartis and Roche/Genentech (USA) generated 2011 sales of US$ 3.67 bln. Approved indications of Lucentis include wet age-related macular degeneration (AMD), diabetic macular edema (DME) and Macular edema following retinal vein occlusion (RVO).

The next generation of anti-VEGF antibodies is lead by the fusion protein aflibercept with recent first approvals in oncology and ophthalmology and a number of other improved molecules including antibodies targeting the receptors of VEGF. Bispecific antibodies targeting VEGF and a second angiogenic target are strongly emerging, but still in earlier phases.

Patents covering Avastion and Lucentis are going to expire in the US and EU over the next couple of years and are paving the way for biosimilar antibodies. The first Avastin biosimilars are already in clinical trials and the pipeline has at least further ten biosimilars in preparation for further development.

A similar pattern of development activities can be seen for ranibizumab: next generation, improved molecules, delivery solutions, extension of indications and biosimilar molecules.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

Table of Contents:
1. Bevacizumab Biosimilars and Biosuperiors
Marketed VEGF Antibody: Avastin Pipeline
Next Generation Avastin Pipeline
- Anti-VEGF Antibody Pipeline
- Anti-VEGF-R Antibody Pipeline
- Bispecific Anti-VEGF Pipeline
Avastin Biosimilar Pipeline

2. Ranibizumab Biosimilars and Biosuperiors
Marketed VEGF Antibody: Lucentis Pipeline
Next Generation Lucentis Pipeline
Lucentis Biosimilar Pipeline

3. Corporate VEGF/-R Antibodies R&D Pipelines

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/competitor-analysis-vegf-antibodies-bevacizumab-and-ranibizumab-biosimilars-and-biosuperiors.html

Related link : www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html


About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com 
Website: www.bharatbook.com 
Follow us on twitter: https://twitter.com/researchbook 
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau 
Our Blog : http://blog.bharatbook.com/ 


Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.